Skip to main content

Table 1 Clinical characteristics of the patient collective

From: Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer

  All patients Occurrence of metastasis  
n = 84 (100%) Metachr. Metastasis (n = 37) Metachr. Metastasis (44%) p (metachr. Met.)
Sex Male 54 (64) 25 (46) 0.578
Female 30 (36) 12 (40)
Age (years, median)   67 (range 35–86) 37 (44) 0.428
Period of enrollment before 1993 42 (50) 22 (52) 0.124
1994 and after 42 (50) 15 (36)
Sidedness Right colon 35 (42) 17 (49) 0.633
Left colon 44 (52) 19 (43)
Unknown 5 (6) 1 (20)
Histology Adenocarcinoma 75 (89) 34 (46) 0.076
Mucinous adenocarcinoma 7 (9) 1 (14)
Signet ring cell 2 7 (2) 2 (100)
Grading Low (G1–2) 48 (57) 18 (38) 0.163
High (G3–4) 36 (43) 19 (53)
pT T1 0 (0) 0 (0) 0.054
T2 6 (7) 4 (67)
T3 57 (68) 20 (35)
T4 21 (25) 13 (62)
pN N1 58 (69) 19 (33) 0.002a
N2 26 (31) 18 (69)
Lymphatic invasion L0 57 (68) 25 (44) 0.960
L+ 27 (32) 12 (44)
Angioinvasion V0 79 (94) 34 (43) 0.459
V+ 5 (6) 3 (60)
Adjuvant chemotherapy None 41 (49) 16 (39) 0.500
5-FU alone 27 (32) 12 (44)
other 16 (19) 9 (56)
Alive status Alive 31 (37) 2 (6) < 0.001
Tumour rel. Death 33 (39) 33 (100)
Non-tumour rel. Death 20 (24) 2 (10)
Occurrence of met. No metastases 47 (56) 0 (0)
Metachronous metastasis 37 (44) 37 (100)
  1. Note: The p-value refers to differences in the distribution of the factors regarding the risk of metachronous metastasis
  2. afavouring pN1